New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists
AUTOR(ES)
Carraway, Hetty
FONTE
BioMed Central
RESUMO
Mammalian target of rapamycin (mTOR) is a serine-threonine kinase member of the cellular phosphatidylinositol 3-kinase (PI3K) pathway, which is involved in multiple biologic functions such as transcriptional and translational control. mTOR is a downstream mediator in the PI3K/Akt signaling pathway and plays a critical role in cell survival. In breast cancer this pathway can be activated by membrane receptors, including the HER (or ErbB) family of growth factor receptors, the insulin-like growth factor receptor, and the estrogen receptor. There is evidence suggesting that Akt promotes breast cancer cell survival and resistance to chemotherapy, trastuzumab, and tamoxifen. Rapamycin is a specific mTOR antagonist that targets this pathway and blocks the downstream signaling elements, resulting in cell cycle arrest in the G1 phase. Targeting the Akt/PI3K pathway with mTOR antagonists may increase the therapeutic efficacy of breast cancer therapy.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=549184Documentos Relacionados
- Targeting the mTOR Signaling Network for Cancer Therapy
- New targets for therapy in breast cancer: Small molecule tyrosine kinase inhibitors
- A participação da proteína cinase mTOR (mammalian target of rapamycin) e do fator transcricional NF-kB na regulação da expressão do GLUT4 em músculo sóleo de ratos.
- Human Cytomegalovirus Infection Induces Rapamycin-Insensitive Phosphorylation of Downstream Effectors of mTOR Kinase
- Mammalian Target of Rapamycin Complex 1 (mTORC1) Activity Is Associated with Phosphorylation of Raptor by mTOR*S⃞